TrialCancer2022

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.

Hyun Cheol Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.